Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amn Healthcare Services (AMN)

AMN Healthcare shareholders approve 2025 Equity Plan and reject special meeting proposal

Neutral Impact 2 of 5 shareholder Written later

At its May 2, 2025 annual meeting, AMN Healthcare shareholders approved the AMN Healthcare 2025 Equity Plan and elected all nine director nominees. They also rejected a shareholder proposal on special shareholder meetings and approved KPMG LLP as auditor for fiscal 2025. The votes set the terms for future equity compensation and governance, and the filing reports no change in company finances.

Key points

  • Equity Plan approved: 28,953,916 for, 849,838 against, 12,447 abstentions
  • Shareholder proposal on special shareholder meetings not approved: 1,976,787 for, 27,818,286 against
  • Advisory vote on named executive officer pay approved: 23,059,546 for, 6,703,892 against
  • KPMG LLP ratified as independent auditor for fiscal year ending December 31, 2025: 31,606,644 for

The filing

CompanyAmn Healthcare Services (AMN)
Form8-K, current report
Filed with the SECMay 5, 2025, 8:00 AM ET
Accession number0001104659-25-044363

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.